✦ LIBER ✦

787 Pharmacodynamic study of serum EGFR and HER2 in patients with non-small cell lung cancer treated with ZD 1839

✍ Scribed by V. Gregorc; G.L. Ceresoli; F. Cappuzzo; I. Floriani; V. Ludovini; K. Bencardino; A. Spreafico; L. Pistola; M. Tonato; E. Villa

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Activity of ZD1839 (Gefitinib, Iressa™)

✍ Angelia D. Gibson; Mark Socinski; Chandra P. Belani; Vinay K. Jain 📂 Article 📅 2002 🏛 CIG Media Group, LP. 🌐 English ⚖ 79 KB

Outcomes of patients with advanced non-s

✍ Jänne, Pasi A.; Gurubhagavatula, Sarada; Yeap, Beow Y.; Lucca, Joan; Ostler, Pat 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 134 KB

PD-157 Serum EGFR in patients with non-s

✍ Spreafico, A.; Gregorc, V.; Ludovini, V.; Pistola, L.; Amoroso, M.; Tofanetti, F 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Selective COX-2 inhibitor celecoxib comb

✍ Likun Chen; Youjian He; He Huang; Hai Liao; Weidong Wei 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 580 KB

ZD 1839 in patients with brain metastase

✍ Cappuzzo, F; Calandri, C; Bartolini, S; Crinò, L 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 102 KB

Effect of gefitinib (‘Iressa’, ZD1839) o

✍ Hotta, Katsuyuki; Kiura, Katsuyuki; Ueoka, Hiroshi; Tabata, Masahiro; Fujiwara, 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 86 KB